Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ Cancer

Ian Chau, MD
Published: Tuesday, Mar 13, 2018


Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian (Eastern) versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.

Investigators assessed the safety profile of nivolumab in an analysis of cohorts from the ATTRACTION-2 and CheckMate-032 trials to compare outcomes between Eastern and Western patients with gastric/GEJ cancer when treated with immunotherapy.

In terms of treatment-emergent adverse events (AEs), Chau says that events were similar in the cohorts compare from ATTRACTION-2 and CheckMate-032. Per the analysis, Eastern and Western patients seemed to have the same AEs while on nivolumab, although the etiology and outcome of gastric/GEJ cancer differs between the 2 groups. Chau says that the time to AEs and duration are worth comparing, as well.

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian (Eastern) versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.

Investigators assessed the safety profile of nivolumab in an analysis of cohorts from the ATTRACTION-2 and CheckMate-032 trials to compare outcomes between Eastern and Western patients with gastric/GEJ cancer when treated with immunotherapy.

In terms of treatment-emergent adverse events (AEs), Chau says that events were similar in the cohorts compare from ATTRACTION-2 and CheckMate-032. Per the analysis, Eastern and Western patients seemed to have the same AEs while on nivolumab, although the etiology and outcome of gastric/GEJ cancer differs between the 2 groups. Chau says that the time to AEs and duration are worth comparing, as well.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x